INTRODUCTION

Thymosin beta 4 (thymosin β4, Tβ4) is a peptide comprising 43 amino acids that abounds in the human body. It has anti-inflammatory property promoting angiogenesis in the ischaemic sites and anti-apoptotic and anti-fibrotic property promoting tissue repair.1 In the recent years, studies have explored the clinical indications of Tβ4, especially in treating ischaemic brain or cardiovascular diseases and have made a breakthrough.2,3 In cardiovascular research, Tβ4 plays an important role in improving blood supply to ischaemic myocardium, reducing myocardial injury, promoting myocardial tissue repair and improving microvascular obstruction,4,5 providing a new therapeutic target for myocardial infarction. Presently, similar products have completed the phase I clinical study of interventions for acute myocardial infarction in the United States. The study results show that Tβ4 is well tolerated and safe with no dose-limiting toxicity.
and serious adverse events. Also, no tumorigenesis was observed within 6 months.6-8

NL005 (recombinant human thymosin β4, rh-Tβ4) comprised 44 amino acids and was generated via restructuring of products by the Beijing northland biotech co., Ltd, using genetic engineering. It has biological activities identical to that of the natural Tβ4. It has undergone complete preclinical pharmacy, pharmacodynamics, pharmacokinetics and safety evaluation, and the preclinical studies have shown NL005 to be stable, of high-quality, safe and effective for increasing the heart function, improving the heart configuration and increasing collateral circulation. It imparts anti-apoptotic property and cell oxidation resistance with no abnormalities during the synthesis. Further developments are however required for harnessing Tβ4 in treating acute myocardial infarction clinically.

2 | MATERIALS AND METHODS

2.1 | Trial design

This study was a single-centre, double-blind, randomized, placebo-controlled, dose-increasing trial. It was divided into single intravenous administration (SAD) and multiple intravenous administration (MAD) (clinicaltrials.gov: CTR20170766; CTR20181784). The SAD was conducted from 11 July 2017 (first patient in) to 20 June 2018 (last patient out). MAD was conducted from 16 October 2018 (first patient in) to 1 April 2019 (last patient out). SAD screened 279 subjects and randomly enrolled 54, MAD screened 242 subjects, 30 were randomly enrolled. This study was approved by the National Medical Products Administration (approval number: 2015L05215), followed by the Helsinki principle and Good clinical practice, approved by the National Medical Ethics Committee of Beijing, Shijitan Hospital, Capital Medical University. The main purpose of this study was to evaluate the safety and tolerability, pharmacokinetics (PK) and anti-drug antibody (ADA).

In the SAD, 54 healthy subjects were enrolled and seven cohorts (0.05, 0.25, 0.5, 2, 5, 12.5 and 25 μg/kg) were administered. Considering the safety, 0.05 and 0.25 μg/kg cohorts (2 subjects per cohort) were used as the pre-test groups, half consisting of males and half of females, and were administered NL005 once. The other five cohorts of subjects (10 subjects per cohort) were administered one dose of NL005 or placebo in a 4:1 ratio.

In the MAD, 30 healthy subjects were enrolled and three cohorts (0.5, 2, 5 μg/kg) were formed, half consisting of males and half of females. Each cohort (10 subjects per cohort) was given NL005 or placebo at a ratio of 4:1 for 10 consecutive days.

2.2 | Subject eligibility

Male (weight ≥50 kg) and female (weight ≥45 kg) volunteers (19 ≤ BMI ≤ 28 kg/m²) between 18 and 50 years and in good health, with no underlying medical conditions that would place them at risk, were evaluated for the study participation. All the subjects provided informed consent. The exclusion criteria included clinically significant abnormalities, smoking history (the previous 3 months > 5 cigarettes per day, or did not stop smoking during the experiment), drinking history (the previous 3 months > 2 units per day (1 unit = 360 mL beer, 150 mL wine or 45 mL liquor with 40% alcohol content) or alcohol test positive) and history of substance abuse or drug screening test positive, pregnancy and lactation plan, ADA positive and allergic to protein preparations and biological products.

2.3 | Procedure

The subjects for SAD were admitted to the clinical pharmacology unit on day 1 of the study and were discharged from the unit on day 5. The NL005 or placebo was administered as a single dose on day 1. The safety parameters including vital signs, physical examination, CBC, chemistries, myocardial injury markers, coagulation function and ECGs were recorded on the days 2, 5, 14 and 28. The tumour markers were examined on day 14. From the 2nd to 7th cohorts, the pharmacokinetic samples were obtained on the day 1, collected from each subject before dose administration; immediately and 15, 30 and 45 minutes post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours post-dose. Blood samples were collected for determining the serum antibody for NL005 at screening day 14 and day 28. Evaluation of the treatment-emergent adverse events was performed throughout the study.

The subjects were admitted to the pharmacology unit on day 1 and remained confined to the unit through day 11 of the MAD. The NL005 or placebo was administered as a single intravenous dose starting from day 1 and then daily for 10 days. The safety parameters including vital signs, physical examination, CBC, chemistries, myocardial injury markers, coagulation function and ECGs were performed intermittently on the days 5, 11 and 28 of the evaluation of adverse events. The tumour markers were examined on day 14 and day 28. The pharmacokinetic samples were obtained from day 1 to 10 from each subject before dosing immediately, 30 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours post-dose. The blood samples were collected for determining the serum antibody against NL005 at screening, days 14 and 28. Subjects were discharged on day 11 and returned for the outpatient evaluations on days 14 and 28. Investigational products (vials of Tβ4 0.1 mg) or placebo (saline solution) were produced and tested by the Beijing Northland Biotechnology and stored at 2-8 ℃. The placebo was indistinguishable from NL005 in shape, colour, package and label.

According to NCI CTCAE4.03, DLT in this study was defined as meeting all the following conditions within 14 days after administration: subjects developed liver, kidney, heart, psychoneurosis toxicity (≥2 grade) or other systemic adverse events (≥3 grade). The relationship was assessed to be possibly, probably or related to the study drug. Definition of maximum tolerated dose (MTD) in this study: occurrence of three or more DLTs in SAD, occurrence of four or more DLTs in MAD should terminate the test, and the previous dose of this dose is regarded as the MTD. During SAD, escalation to the next
dosing cohort occurred after a blinded review of all the cohort safety data through day 14. During MAD, a safety review of all the cohort data occurred after day 28.

2.4 | Statistical analysis

All statistical analyses were done with the SAS 9.4 (SAS Institute) in the Statistical Analysis Department, Jiaxing Taimei Medical Technology. The pharmacokinetic parameters and ADA indexes were tested and analysed by Joinn Laboratories (China) Co., Ltd. The pharmacokinetic parameters were estimated using the Phoenix WinNonlin software (Certara).

All the pharmacokinetic samples in the single and multiple dosing tests were collected, centrifuged and packed by the research centre and transported to the testing unit in the frozen state on dry ice (≤−70℃). They were tested and analysed for the plasma concentration using the validated LC-MS/MS (Waters, UPLC-Xevo TQ-S) analysis method, and the quantitative lower limit is 0.22 ng/mL for the SAD and 0.3 ng/mL for MAD. The non-compartment model (NCA) was used to calculate the pharmacokinetic parameters, and the main parameters obtained were $C_{\text{max}}$, $T_{\text{max}}$, AUC, $t_{1/2}$, CL and $V_z$.

All the ADA samples are transported to the testing unit in the cold chain under dry ice (≤−70℃) and were screened and confirmed with the indirect ELISA analysis method, and the positive samples were tested for the antibody titre.

3 | RESULTS

3.1 | Demographic and baseline characteristics

Fifty-four subjects were enrolled in SAD (10 placebos, 44 NL005), half of which were males and the other half were females. Thirty subjects were enrolled in MAD (6 placebos, 24 NL005). The study volunteers had fairly consistent characteristics across all cohorts in terms of age, weight and BMI etc (Table 1).

3.2 | Safety and tolerability

The adverse events (AEs) were coded by the MedDRA 21.0, and the relationship was assessed by CTCAE4.03, and the clinical safety was evaluated. There were no serious adverse events or dose-limiting toxicities during the SAD. Seven of 10 (70%) placebo subjects demonstrated AEs, 25 of 44 (56.8%) Tβ4 cohorts too. All the AEs were mild and moderate, only one placebo subject experienced remission after medication for upper respiratory tract infection, and the rest experienced spontaneous remission. The incidence and severity of adverse events were equal in the Tβ4 group and the placebo group (Table 2).

There were no serious adverse events or dose-limiting toxicities during the MAD. Five of six (83.3%) placebo subjects experienced AEs, and the experimental group incidence was 16 of 24 (66.7%). All the AEs were mild and moderate, untreated and alleviated by themselves. At 5 μg/kg, both placebo and Tβ4 groups had one case of subject shedding due to an abnormal electrocardiogram. The incidence and severity of adverse events were equal in the Tβ4 group and the placebo group (Table 3).

3.3 | Pharmacokinetics

In the SAD, the mean plasma concentration increases proportionally with the increase in the dose and drug administration time ranging from 0.25 to 25 μg/kg (Figure 1). The $C_{\text{max}}$, AUC0-t, and AUC0-∞ demonstrated a trend of linear dynamic characteristics, but the conclusion of linear pharmacokinetic characteristics remains elusive (Table 4). The mean plasma concentration, $C_{\text{max}}$, and AUC, each increased proportionally with dose, over the range of doses studied in

| TABLE 1 | Demographics |
| --- | --- |
| Gender | Race |
| Male | Female | Age (y) | Han | Other | Weight (kg) | Height (cm) | BMI (kg/m²) |
| Placebo (N = 10) | 5 | 5 | 27.4 | 9 | 1 | 67.35 | 164.1 | 24.91 |
| 0.05 μg/kg (N = 2) | 1 | 1 | 31.0 | 2 | 0 | 67.90 | 166.0 | 24.60 |
| 0.25 μg/kg (N = 2) | 1 | 1 | 28.0 | 2 | 0 | 69.80 | 168.5 | 24.60 |
| 0.5 μg/kg (N = 8) | 4 | 4 | 25.8 | 8 | 0 | 64.48 | 165.8 | 23.45 |
| 2.0 μg/kg (N = 8) | 4 | 4 | 28.6 | 7 | 1 | 61.56 | 165.3 | 22.51 |
| 5.0 μg/kg (N = 8) | 4 | 4 | 27.8 | 7 | 1 | 62.25 | 160.9 | 24.10 |
| 12.5 μg/kg (N = 8) | 4 | 4 | 32.8 | 8 | 0 | 63.28 | 164.5 | 23.31 |
| 25.0 μg/kg (N = 8) | 4 | 4 | 28.8 | 7 | 1 | 63.35 | 163.5 | 23.69 |
| Placebo (N = 6) | 3 | 3 | 30.7 | 6 | 0 | 71.68 | 170.7 | 24.58 |
| 0.5 μg/kg (N = 8) | 4 | 4 | 28.1 | 8 | 0 | 64.58 | 170.6 | 22.14 |
| 2.0 μg/kg (N = 8) | 4 | 4 | 29.1 | 7 | 1 | 63.06 | 166.3 | 22.74 |
| 5.0 μg/kg (N = 8) | 4 | 4 | 29.9 | 8 | 0 | 61.61 | 165.4 | 22.54 |
TABLE 2 Summary of the single-dose adverse events

| Adverse events                   | Placebo (N = 10) | 0.05 μg/kg (N = 2) | 0.25 μg/kg (N = 2) | 0.5 μg/kg (N = 8) | 2.0 μg/kg (N = 8) | 5.0 μg/kg (N = 8) | 12.5 μg/kg (N = 8) | 25 μg/kg (N = 8) | Total study drug (N = 44) |
|---------------------------------|------------------|--------------------|--------------------|-------------------|------------------|------------------|-------------------|------------------|-------------------------|
| Number of subjects             | 7                | 2                  | 2                  | 6                 | 5                | 3                | 4                 | 3                | 25                      |
| Total adverse events           | 12               | 4                  | 3                  | 9                 | 10               | 6                | 8                 | 5                | 45                      |
| Abnormal blood biochemical     | 4                | 1                  | 2                  | 1                 | 2                | 1                | 2                 | 0                | 9                       |
| Abnormal blood routine         | 1                | 3                  | 0                  | 1                 | 3                | 1                | 1                 | 1                | 9                       |
| Abnormal SCC                   | 0                | 0                  | 0                  | 1                 | 1                | 0                | 3                 | 3                | 8                       |
| Abnormal routine urine         | 4                | 0                  | 0                  | 1                 | 3                | 1                | 1                 | 1                | 7                       |
| Abnormal other tumour markers  | 1                | 0                  | 0                  | 3                 | 0                | 0                | 0                 | 0                | 4                       |
| Abnormal ECG                   | 1                | 0                  | 0                  | 2                 | 1                | 0                | 0                 | 0                | 3                       |
| Cervicitis                     | 0                | 0                  | 0                  | 0                 | 0                | 1                | 0                 | 0                | 1                       |
| Pelvic inflammation            | 0                | 0                  | 0                  | 0                 | 0                | 1                | 0                 | 0                | 1                       |
| Upper respiratory infection    | 1                | 0                  | 0                  | 0                 | 0                | 0                | 1                 | 0                | 1                       |
| Vaginal infection              | 0                | 0                  | 0                  | 0                 | 0                | 1                | 0                 | 0                | 1                       |
| Phlebitis                      | 0                | 0                  | 1                  | 0                 | 0                | 0                | 0                 | 0                | 1                       |
| Abnormal cardiac injury marker | 0                | 0                  | 0                  | 0                 | 0                | 0                | 0                 | 0                | 0                       |
| Abnormal coagulation           | 0                | 0                  | 0                  | 0                 | 0                | 0                | 0                 | 0                | 0                       |
After continuous administration for 10 days, before each administration, the plasma drug concentration dropped to the lower limit of the dose, the tendency of terminal clearance was relatively consistent, and no obvious accumulation was observed for artemisate between the dosage of 0.5-5.0 μg/kg after continuous administration (Figure 2).

### 3.4 The anti-drug antibody of NL005

A total of 108 ADA samples (D14/D28) were collected from 54 subjects in SAD, and except for one positive sample, all the others were negative, and the positive detection rate was 1/108. All the positive samples became negative after follow-up.

### DISCUSSION

The pharmacokinetic results of both SAD and MAD showed a proportional increase in the mean plasma concentration, $C_{\text{max}}$ and AUC each, with the increasing dose. Among the cohorts, the $T_{\text{max}}$ was from 3 to 15 minutes, and $t_{1/2}$ was from 0.5 to 2.08 hours; and it was consistent with the reports on chemical Tβ4 products. In the MAD, continuous administration for 10 days demonstrated a relatively consistent trend of terminal clearance with no obvious accumulation after continuous administration. The anti-drug antibody results indicate that NL005 does not produce resistant antibodies. For samples with positive anti-drug antibody in the follow-up period, the values of the test indices were just above the positive criterion at the first test; however, when the titres were measured, the detection indices were below the positive criterion, which suggests that systematic error caused the difference. The fact that all the positive samples turned negative after follow-up suggests that this product did not produce resistant antibodies.

There were no serious adverse events or dose-limiting toxicities observed during the SAD and MAD. All the AEs were mild and moderate, untreated and alleviated by themselves. The incidence and severity of the adverse events were equal in the Tβ4 and the placebo groups.

In this study, there was a mild transient increase in SCC after administration in both NL005 and placebo groups, such that all of them returned to normal after follow-up. SCC is a tumour marker of epithelial hyperplasia with low sensitivity and specificity, and the time curve of mildly increased SCC was consistent with the concentration of this product in the blood, which was considered to be related to the mechanism of Tβ4 promoting the regeneration of

### TABLE 3 Summary of multiple-dose adverse events

| Adverse events                      | Placebo (N = 6) | 0.5 μg/kg (N = 8) | 2.0 μg/kg (N = 8) | 5.0 μg/kg (N = 8) | Total study drug (N = 24) |
|-------------------------------------|----------------|------------------|------------------|------------------|--------------------------|
| Number of subjects reporting        | 5              | 5                | 6                | 5                | 16                       |
| Total adverse events                | 11             | 10               | 16               | 13               | 39                       |
| Abnormal routine urine              | 2              | 1                | 6                | 1                | 8                        |
| Abnormal ECG                        | 5              | 0                | 1                | 7                | 8                        |
| Abnormal blood routine              | 0              | 2                | 2                | 2                | 6                        |
| Abnormal blood biochemical          | 1              | 2                | 2                | 0                | 4                        |
| Abnormal tumour markers(SCC)        | 2              | 2                | 0                | 2                | 4                        |
| Hypertriglyceridaemia               | 1              | 1                | 2                | 0                | 3                        |
| Abnormal cardiac injury marker      | 0              | 0                | 1                | 0                | 1                        |
| Abnormal coagulation                | 0              | 2                | 0                | 0                | 2                        |
| Transient amaurosis                 | 0              | 0                | 0                | 1                | 1                        |
| Blood vessel puncture site bruising | 0              | 0                | 1                | 0                | 1                        |
| Sinus bradycardia                   | 0              | 0                | 1                | 0                | 1                        |
epithelial cells. Recent research showed that Tp4 participates in the metastasis of tumours and has a potential for tumour promotion by inducing angiogenesis and epithelial cell migration. However, some studies have shown that Tp4 may have an anti-tumour effect, and no tumour-related adverse events were found in this study.

As far as we know, this study is the first reported investigation of Tp4, produced using recombinant gene technology in healthy subjects. This study showed that NL005 is well tolerated and safe and should be allowed to develop further drugs to treat acute myocardial infarction.

ACKNOWLEDGEMENTS
Beijing Northland Biotechnology Co., Ltd. is the sponsor of the study.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare. Chengquan Han, Yinjian Sun and Jincan Liu are employees of the sponsor.

TABLE 4 Summary of the main pharmacokinetic parameters for single/multiple administration

| Time    | Dose (μg/kg) | Cmax (ng/mL) | AUC0−(h*ng/mL) | AUC0−(h*ng/mL) | Tmax (h) | t1/2 (h) | CLss (mL/h/kg) | Vss (mL/kg) |
|---------|--------------|--------------|----------------|----------------|----------|----------|----------------|-------------|
| Single  | 0.25         | 1.99         | 1.26           | 1.47           | 0.05     | 0.5      | 175.985        | 119.925     |
|         | 0.5          | 3.581        | 2.419          | 2.838          | 0.05     | 1.019    | 188.161        | 256.771     |
|         | 2.0          | 11.709       | 11.129         | 12.075         | 0.25     | 1.963    | 198.163        | 432.453     |
|         | 5.0          | 48.406       | 32.278         | 33.054         | 0.05     | 2.983    | 115.934        | 305.674     |
|         | 12.5         | 86.896       | 73.604         | 74.863         | 0.05     | 1.92     | 117.883        | 462.041     |
|         | 25.0         | 230.065      | 155.153        | 156.461        | 0.05     | 2.084    | 163.555        | 481.041     |
| Multiple| 0.5          | 3.351        | 1.75           | 2.135          | 0.568    | 216.05   | 257.066        | 192.256     |
|         | 2.0          | 11.698       | 10.031         | 11.008         | 1.281    | 205.993  | 198.609        | 346.686     |
|         | 5.0          | 38.243       | 25.607         | 26.513         | 1.413    | 205.993  | 205.993        | 410.639     |

FIGURE 2 The mean ± SD of the plasma concentrations (ng/mL) of Tp4 following multiple intravenous administration to healthy human subjects

Chengquan Han: Conceptualization (supporting); Resources (supporting); Supervision (supporting); Formal analysis (supporting); Funding acquisition (supporting); Investigation (supporting); Methodology (supporting); Project administration (supporting); Resources (supporting); Software (supporting); Supervision (supporting); Validation (supporting); Visualization (supporting). Yinjian Sun: Conceptualization (supporting); Data curation (supporting); Formal analysis (supporting); Funding acquisition (supporting); Investigation (supporting); Methodology (supporting); Project administration (supporting); Resources (supporting); Software (supporting); Supervision (supporting); Validation (supporting); Visualization (supporting).
administration (lead); Resources (supporting); Software (supporting); Supervision (supporting); Validation (supporting); Visualization (supporting). **Jincan Liu:** Conceptualization (supporting); Data curation (supporting); Formal analysis (supporting); Funding acquisition (lead); Investigation (supporting); Methodology (supporting); Project administration (lead); Resources (supporting); Software (supporting); Supervision (supporting); Validation (supporting); Visualization (supporting).

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ORCID**

Xinghe Wang  [https://orcid.org/0000-0002-4197-8545](https://orcid.org/0000-0002-4197-8545)

**REFERENCES**

1. Dube KN, Bollini S, Smart N, et al. Thymosin β4 protein therapy for cardiac repair. *Curr Pharm Des*. 2012;18:799-806.
2. Smart N, Risebro CA, Melville AAD, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. *Nature*. 2007;445:177-182.
3. Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. *Nature*. 2004;432:466-472.
4. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. *Nature*. 2011;474:640-644.
5. Smart N, Dube KN, Riley PR. Epicardial progenitor cells in cardiac regeneration and neovascularization. *Vascul Pharmacol*. 2013;58:164-173.
6. Ruff D, Crockford D, Girardi G, et al. A randomized, placebo-controlled, single and multiple-dose study of intravenous thymosin β4 in healthy volunteers. *Ann NY Acad Sci*. 2010;1194:223-229.
7. [http://www.regenerx.com/RGN-352](http://www.regenerx.com/RGN-352)
8. [https://www.clinicaltrials.gov/; Identifier: NCT01311518](https://www.clinicaltrials.gov/; Identifier: NCT01311518).
9. Kulpa J, Wójcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. *Clin Chem*. 2002;48:1931-1937.
10. De Cos JS, Masa F, de la Cruz JL, et al. Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. *Chest*. 1994;105:773-776.
11. Sosne G, Hafee S, Greenberry AL, et al. Thymosin β4 promotes human conjunctival epithelial cell migration. *Curr Eye Res*. 2002;24:268-273.
12. Philip D, Kleinman HK. Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide. *Ann NY Acad Sci*. 2010;1194:81.
13. Sosne G, Xu L, Prach L, et al. Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta. *Exp Cell Res*. 2004;293(1):175-183.
14. Caers J, Hose D, Kuipers I, et al. Thymosin β4 has tumour-suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. *Haematologica*. 2010;95:163-167.
15. Morita T, Hayashi K. Tumor progression is mediated by thymosin-β4 through a TGFβ/MRTF signaling axis. *Mol Cancer Res*. 2018;16:880-893.
16. Cha H-J, Jeong M-J, Kleinman HK. Role of thymosin 4 in tumor metastasis and angiogenesis. *J Natl Cancer Inst*. 2003;95(19).

**How to cite this article:** Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. *J Cell Mol Med*. 2021;25:8222-8228. [https://doi.org/10.1111/jcmm.16693](https://doi.org/10.1111/jcmm.16693)